Microneedle Patch

PharmaTher Holdings (OTCQB: PHRRF) and the Terasaki Institute for Biomedical Innovation evaluated the former’s novel microneedle patch for the delivery of DMT, and research yielded positive outcomes. The study sought to develop a suitable prototype of PharmaPatch for DMT’s transdermal...

Specialty biotech company PharmaTher Holdings Ltd. (OTCQB: PHRRF) has filed a pre-submission facility correspondence in advance of its Abbreviated New Drug Application (ANDA) for its novel racemic ketamine KETARX to the FDA. The filing of the pre-submission correspondence is expected to help...

Ketamine products manufacturer PharmaTher Holdings Ltd. (OTCQB: PHRRF) had lots happening this past week. Here are the company's top three news items. FDA’s Orphan Drug Status To Ketamine For Rett Syndrome The FDA granted an orphan drug designation to the company’s proprietary...